Institut Biochimique SA
https://www.ibsagroup.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Institut Biochimique SA
Yaral To Expand Burgeoning Generics Portfolio With Support From Eversana
With three additional commercial launches lined up for 2023, Yaral has opted to expand its pre-existing partnership with life sciences service provider Eversana to support these activities.
Start-Up Quarterly Statistics, Q1 2016
Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).
Medical Device Deals Update, March 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2016.
FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
- Other Names / Subsidiaries
-
- AMSA Italy
- Gelfipharma Italy
- IBSA
- IBSA Italy
- IBSA Pharma Hungary
- IBSA Slovakia
- Laboratoires Genevrier France
- Rizhao Lanshan China
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice